A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial With an Open-Label Extension Phase of Perampanel as Adjunctive Treatment in Subjects at Least 2 Years of Age With Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome
Latest Information Update: 14 Jun 2023
At a glance
- Drugs Perampanel (Primary)
- Indications Lennox-Gastaut syndrome; Seizures
- Focus Registrational; Therapeutic Use
- Sponsors Eisai Co Ltd; Eisai Inc
- 27 Apr 2023 Results of post-hoc analysis assessing early and sustained treatment effect of adjunctive perampanel presented at the 75th Annual Meeting of the American Academy of Neurology 2023.
- 20 Apr 2023 According to a Catalyst Pharmaceuticals media release, data from this study (to be presented in AAN 2023) is presented online https://index.mirasmart.com/aan2023/PDFfiles/AAN2023-002293.html.
- 20 Apr 2023 According to a Catalyst Pharmaceuticals media release, abstract will be presented at the upcoming AAN 2023 Annual Meeting taking place in Boston, MA and virtually on April 22-27, 2023.